Kara W Chew
Overview
Explore the profile of Kara W Chew including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luetkemeyer A, Chew K, Lacey S, Hughes M, Harrison L, Daar E, et al.
Clin Infect Dis
. 2025 Feb;
PMID: 39960062
Background: Ensitrelvir, a severe acute respiratory syndrome coronavirus-2 main protease inhibitor, has demonstrated clinical and virologic efficacy in previous studies. Methods: In this global phase 3 trial, nonhospitalized adults with...
2.
Ramirez S, Lopez P, Faraji F, Parikh U, Heaps A, Ritz J, et al.
JCI Insight
. 2024 Dec;
9(24).
PMID: 39704169
T cells are involved in protective immunity against numerous viral infections. Data regarding functional roles of human T cells in SARS-CoV-2 (SARS2) viral clearance in primary COVID-19 are limited. To...
3.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al.
Clin Infect Dis
. 2024 Nov;
80(2):323-330.
PMID: 39523543
Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral treatment for mild to moderate coronavirus disease 2019 (COVID-19). Methods: This phase 2/3, double-blind, randomized (1:1) study assessed oral NMV/r 300 mg/100 mg...
4.
Bhimraj A, Falck-Ytter Y, Kim A, Li J, Baden L, Johnson S, et al.
Clin Infect Dis
. 2024 Oct;
PMID: 39471458
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America....
5.
Chew K, McGinley B, Moser C, Li J, Evering T, Ritz J, et al.
J Infect Dis
. 2024 Oct;
231(1):131-136.
PMID: 39400063
We explored viral and symptom rebound after coronavirus disease 2019 amubarvimab-romlusevimab monoclonal antibody therapy versus placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal severe acute respiratory syndrome coronavirus 2...
6.
Lin H, Chen Y, Abror-Lacks G, Price M, Morris A, Sun J, et al.
Commun Biol
. 2024 Sep;
7(1):1145.
PMID: 39277660
Pathogenic changes in gut microbial composition precede the onset of HIV-1 infection in men who have sex with men (MSM). This process is associated with increased levels of systemic inflammatory...
7.
Evering T, Moser C, Jilg N, Ritz J, Wohl D, Li J, et al.
EClinicalMedicine
. 2024 Sep;
75:102787.
PMID: 39252866
Background: It is unknown if early COVID-19 monoclonal antibody (mAb) therapy can reduce risk of Long COVID. The mAbs amubarvimab/romlusevimab were previously demonstrated to reduce risk of hospitalization/death by 79%....
8.
Paul M, Choudhary M, Heaps A, Deo R, Moisi D, Gordon K, et al.
Pathog Immun
. 2024 Sep;
9(2):79-93.
PMID: 39247686
Background: Anti-SARS-CoV-2 monoclonal antibodies (mAbs) have played a key role as an anti-viral against SARS-CoV-2, but there is a potential for resistance to develop. The interplay between host antibody responses...
9.
Parikh U, Heaps A, Moisi D, Gordon K, Mellors J, Choudhary M, et al.
Pathog Immun
. 2024 Aug;
9(2):58-78.
PMID: 39165724
Background: Assessing the breadth and duration of antigen-specific binding antibodies provides valuable information for evaluating interventions to treat or prevent SARS-CoV-2 infection. Multiplex immunoassays are a convenient method for rapid...
10.
Bloom N, Ramirez S, Cohn H, Parikh U, Heaps A, Sieg S, et al.
J Infect Dis
. 2024 Jul;
230(5):1187-1196.
PMID: 39036987
Therapeutic monoclonal antibodies (mAbs) have been studied in humans, but the impact on immune memory of mAb treatment during an ongoing infection remains unclear. We evaluated the effect of infusion...